Summary Following the demonstration of efficacy, tolerability and quality-of-life benefits of raltitrexed ('Tomudex'), principally in advanced colorectal but also in other cancers, an extensive evaluation of combination therapy with other agents in patients with colorectal and other tumour types is being undertaken. This work has been prompted by preclinical observations of enhanced activity of raltitrexed when coadministered with other cytotoxic agents or radiotherapy and by preliminary results showing the activity of raltitrexed in patients with cancers other than colorectal. Raltitrexed is currently being investigated as monotherapy in phase and 11 cancer studies, including head and neck cancer, hormone-resistant prostate cancer, paediatric and adult leukaemias and solid tumours, and soft tissue sarcoma. In addition, phase clinical trials are evaluating the drug in combination with taxanes (paclitaxel) in solid tumours, anthracyclines (doxorubicin) in gastric carcinoma, topoisomerase inhibitors (CPT-11) and 5-fluorouracil (both infusion and bolus regimens) in advanced colorectal cancer, platinum compounds (oxaliplatin and cisplatin) in a variety of tumours and radiotherapy in rectal cancer. Preliminary reports indicate good tolerability and acceptability of the combinations being investigated, with no dose-limiting toxicity being reported to date, and some early indications of efficacy.
Raltitrexed ('Tomudex') has been designed to inhibit directly and non-competitively a specific molecular target, thymidylate synthase (TS). The development of TS inhibitors for cancer therapy has been described in several reviews (Jackman and Judson, 1996; Touroutoglou and Pazdur, 1996; Rustum et al, 1997) . TS converts deoxyuridine monophosphate (dUMP) into thymidine monophosphate (TMP), after which other enzymes convert TMP to thymidine triphosphate, a key requirement for DNA synthesis. 5-Fluorouracil (5-FU) is metabolized to 5-fluorodeoxyuridine monophosphate (FdUMP) , which forms an inactive complex with TS and stops the synthesis of TMP by blocking access of dUMP to TS. However, the concentration of dUMP in the cell then rises to the point at which it is able to overcome FdUMP. 5-FU is also converted to other metabolites that can affect RNA and subsequently protein synthesis; these may enhance antitumour activity but may also cause toxicity. Unlike 5-FU, raltitrexed inhibits TS directly and does not require the presence of a second agent (Figure 1 ) (Jackman et al, 1995) . Furthermore, the drug is specific for TS and does not appear to affect other cellular pathways. Raltitrexed is taken up into cells by the reduced folate carrier system in the cell membrane. This carrier is found more frequently on some tumour cells, an observation that may help to explain the selectivity of raltitrexed. While raltitrexed is active in its parent form, once inside the cell it is rapidly converted into polyglutamated forms. These polyglutamates are more potent inhibitors of TS than the parent drug, are retained within cells for longer and cause enhanced and extended inhibition of TS (Jackman et al, 1991 (Jackman et al, , 1995 , which permits a more convenient (once every 3 weeks) dosing schedule than is possible for regimens based on 5-FU. 
MONOTHERAPY FOR ADVANCED COLORECTAL CANCER
Raltitrexed is now available in more than ten countries for the first-line treatment of advanced colorectal cancer (CRC) . Until recently, the only effective chemotherapy for this disease was 5-FU, administered in conjunction with a modulating agent [usually leucovorin (LV) ]. Chemotherapy regimens based on 5-FU have prolonged survival significantly compared with best supportive care alone in advanced CRC (Nordic Gastrointestinal Tumour Adjuvant Therapy Group, 1992; Scheithauer et al, 1993; AllenMersh et al, 1994) , but complex and inconvenient administration schedules are associated with the use of this drug.
The efficacy of raltitrexed as monotherapy in patients with advanced CRC has been shown in three phase III clinical studies (Cunningham et al, 1996a; Harper and Study Group, 1997; Kerr, 1997; Pazdur and Vincent, 1997) in which raltitrexed was compared with two standard 5-FU-based regimens. Two international trials, studies 3 (439 patients) and 12 (495 patients), compared raltitrexed 3 mg m-2 once every 3 weeks with 5-FU 425 mg m-2 plus LV 20 mg m-2 (Mayo regimen) and 5-FU 400 mg m-2 plus LV 200 mg m-2 (Machover regimen), respectively, every 4-5 weeks. A North American trial, study 10, originally randomized patients to three treatment arms: raltitrexed 3 and 4 mg m-2 and 5-FU + LV (Mayo regimen). The 4 mg m-2 dose of raltitrexed was discontinued because of unacceptable toxicity, and the subsequent analysis was based on a two-group comparison in a total of 427 patients. Objective response rates, times to progression and survival data are shown in Table 1 (Cunningham et al, 1996b) . Complete and partial responses were seen in patients with breast (26%), ovarian (7%), non-smallcell lung (9%) and pancreatic cancer (12%). Although there were no complete or partial responses to treatment with raltitrexed in a phase II study of 33 patients with hepatocellular carcinoma, there were 'good' minor responses in two patients (8%), one of whom had a marked and sustained decrease (from 188 to 5 gg 1-') in plasma ax-fetoprotein levels (Rougier et al, 1997) . Three other patients also showed decreases of at least 25% in plasma levels of this tumour marker (range 60-98%).
The concept of combination therapy offers three opportunities for improved efficacy. Firstly, drugs with non-overlapping toxicities that have already shown activity against a particular tumour type may be coadministered. Secondly, agents that act at different phases of the cell cycle may be used, which leads to biochemical synergy. Thirdly, agents that act at the same phase of the cell cycle, but through differing mechanisms, may be used; this leads to an additive effect (Figure 2 ). For example, raltitrexed and 5-FU both act at S-phase through their inhibition of TS; however, each drug enters the cell and achieves this effect in a different way. These, and other drugs in combination, will be considered in more detail in the following discussion.
COMBINATION TREATMENTS UNDER INVESTIGATION
The clinical trials currently underway to investigate the efficacy of raltitrexed in a range of different tumour types are shown in Table  2 . Treatments to be discussed in detail are as follows: raltitrexed with taxanes (e.g. paclitaxel); raltitrexed with anthracyclines (e.g. doxorubicin); and combinations in colon and rectal cancer that include raltitrexed with platinum compounds (e.g. oxaliplatin, cisplatin); raltitrexed with topoisomerase I inhibitors (e.g. CPT-11); raltitrexed with 5-FU (bolus and infusion); and raltitrexed with radiotherapy.
Raltitrexed with taxanes
The taxanes, which include paclitaxel and docetaxel, block cell replication at G2/M phase by inhibiting normal spindle formation through the formation of abnormally stable microtubule bundles (Schiff and Horwitz, 1980; Horwitz, 1995) . The most impressive clinical activity of paclitaxel has been seen in advanced ovarian and breast cancers (Rowinsky, 1995) . Phase II data show similar activity for docetaxel, with both drugs being active in advanced breast cancer refractory to anthracycline therapy (Rowinsky et al, 1990; Rowinsky and Donehower, 1995; Seidman 1995) . Antitumour activity has also been observed in a range of tumours that are generally refractory to other treatments, including non-smalland small-cell lung, head and neck, oesophageal, bladder and germ cell cancers as well as lymphoma and Kaposi's sarcoma (Rowinsky et al, 1990; Rowinsky and Donehower, 1995) .
The taxanes show toxicity profiles that differ from that of raltitrexed, with myelosuppression being their most notable side-effect. Paclitaxel induces neutropenia, hypersensitivity reactions, peripheral neuropathy and cardiac rhythm disturbances (Rowinsky and Donehower, 1995; Ratain, 1997) . Docetaxel is associated with fluid retention and skin toxicity and, although nausea, vomiting and diarrhoea may be observed, severe gastrointestinal toxicity is rare (Ratain, 1997) . Thus, as well as being of mechanistic interest as candidates for combination with raltitrexed, these agents also have toxicity profiles that largely do not overlap with that of raltitrexed.
As shown in Table 2 , combination therapy with raltitrexed and paclitaxel is currently under investigation in a phase I clinical study designed to determine maximum-tolerated dose (MTD) in patients with refractory solid tumours. This single-centre USA study is recruiting patients who have undergone previous standard treatment and includes a follow-up to assess safety [adverse events (WHO criteria) and haematology and biochemistry]. Dose levels of raltitrexed 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 mg m-2 are being administered with paclitaxel at a fixed dosage of 175 mg m-2 every 3 weeks (this is the highest recommended dosage of paclitaxel in the USA; further escalation of raltitrexed dose in 0.5 mg m-2 increments will be undertaken if the MTD is not reached at 3.0 mg m-2). Future development may include combination of the agreed dosage of raltitrexed plus paclitaxel with carboplatin in a followon phase I study that could lead to randomized comparisons with standard therapy in patients with non-small-cell lung cancer.
Raltitrexed with anthracyclines
The anthracyclines, which include doxorubicin and daunorubicin, have been in clinical use since the 1960s and form one of the most commonly used groups of anti-cancer drugs. They have several postulated mechanisms of action, the most important of which is believed to be interference with the function of the enzyme topoisomerase II (Ratain, 1997) . A representation of the action of anthracyclines is shown in Figure 3 . New developments with raltitrexed 31 Mitosis: cell division Resting phase Figure 2 The cell cycle and some anti-cancer treatments that act on its various phases. 5-FU, 5-fluorouracil Dose-limiting toxicity of the anthracyclines manifests chiefly as myelosuppression, with neutrophils being primarily affected. Gastrointestinal toxicity, including mucositis, is also common (Ratain, 1997) . It should be noted that mucositis is markedly less severe with raltitrexed than with 5-FU (Cunningham et al, 1996a) which may make raltitrexed the more suitable of these two TS inhibitors for such a combination study. Anthracyclines are also associated with acute and chronic cardiotoxicity, notably dosedependent congestive cardiomyopathy.
A phase I multicentre study of raltitrexed 2.5 mg m-2 with doxorubicin every 3 weeks in patients with locally advanced or metastatic gastric cancer is being undertaken by the National Cancer Institute of Canada (NCIC). Up to 40 patients with no previous systemic treatment will be recruited to this study, the aim of which is to evaluate objective tumour response and safety. To date, patients have received either 30 or 40 mg m-2 of doxorubicin, with no dose-limiting toxicity (DLT) seen at level 1 (raltitrexed 2.5 mg m-2 with doxorubicin 30 g m-2). Further dose escalations are planned. Future developments include a study of raltitrexed in combination with the second-generation anthracycline epirubicin.
Raltitrexed with platinum compounds
Cisplatin (Figure 4 ) was the first anti-cancer platinum compound to enter clinical trials in the 1970s and remains important in the curative therapy of advanced germ cell tumours. Several thousand platinum complexes have been synthesized over the last 20 years in attempts to develop less toxic, non-cross-resistant or oral analogues, one of which is oxaliplatin (McKeage, 1995) .
Platinum-containing compounds act by cross-linking (adduction) with DNA strands (cisplatin reacts readily with the purine N7 position to form a variety of mono-and bifunctional DNA adducts, the majority of which are intrastrand cross-links) (Ratain, 1997) . The resulting damage to DNA strands (including local kinking and unwinding) causes inhibition of transcription and replication ( Figure 5 ). Cisplatin is the longest-established drug of this type but is associated with severe toxicity (nausea and vomiting, nephrotoxicity, myelosuppression, neurotoxicity and ototoxicity). Oxaliplatin is a third-generation compound that causes minimal myelosuppression and has not been associated with nephrotoxicity; toxicity manifests mainly as nausea and vomiting, diarrhoea and neurotoxicity (Ratain, 1997) . These agents have been combined with 5-FU in pretreated patients with resistant tumours, most notably oxaliplatin in patients with advanced CRC (Levi et al, 1992 (Levi et al, , 1994 (Levi et al, , 1995 de Gramont et al, 1994) .
Platinum compounds and raltitrexed therefore act by different mechanisms: platinum compounds by damaging DNA and raltitrexed by interfering with DNA synthesis and repair. The different toxicity profiles of these compounds add further support to the rationale for their use in combination. Indeed, results of in vitro cell line work indicate synergy between both oxaliplatin and 5-FU in human colonic (HT-29), ovarian (2008, A2780) and hormone-refractory breast (MDA-MB-231) cancer cells (Kelland et al, 1995; Ackland et al, 1996; Raymond et al, 1996) . Simultaneous 72-h exposure of A2780 cells to raltitrexed and cisplatin showed synergism at some concentration ratios and additivity or antagonism at others (Table 3) .
A phase I dose escalation study is currently under way in France in patients with advanced cancer refractory to previous therapy. Fifteen patients with a variety of tumour types (mesothelioma, small-cell lung, ovarian, stomach, adrenal and duodenal/jejunum cancer) have been recruited to five dosage levels (all treatments given once every 3 weeks) ( Table 4 ). The study is designed to determine the recommended dosage and side-effect profile (with particular reference to haematological, biochemical and neurological toxicities) for raltitrexed with oxaliplatin. In addition, a phase I study of raltitrexed in combination with cisplatin in patients with non-small-cell lung cancer is being carried out in Germany; three patients have so far been recruited to the first dose level of raltitrexed 2.6 mg m-2 with cisplatin 60 mg m-2. To date, no DLT has been reported in either study. synergistic activity, with the magnitude of potentiation being greater when short-term (4-h) exposure was used and SN 38 given first. Higher relative doses of raltitrexed also resulted in increased cytotoxicity (Table 5 ). These data indicate the importance of optimal scheduling of drug combinations and formed the basis of the schedule selected for the phase I clinical study described later in this section. Dose-limiting toxicities in phase II trials of CPT-11 have been diarrhoea and neutropenia. Nausea and vomiting also occur frequently. However, mucositis was rare with this drug (Rougier and Bugat, 1996) . The major toxicities associated with raltitrexed were elevated transaminases and diarrhoea (Zalcberg, 1997) . These-toxicity profiles partly overlap, and a phase I dose escalation study is under way to optimize dosages of these drugs when given in combination. This single-centre UK study in 25 patients with advanced metastatic CRC resistant to infusional 5-FU will determine MTD, toxicity and objective response rate. CPT-11 is administered 1 h before raltitrexed, and drugs are administered once every 3 weeks. Dosage levels are shown in Table 6 . Partial remission of disease has been reported for a patient on the highest dose level, and there have been no observations of major toxicity, which leads to the interesting speculation that raltitrexed may moderate the toxicity of CPT-1 1.
previously untreated and 5-FU-resistant tumours (Armand et al, 1995; Rougier and Bugat, 1996; Van Cutsem et al, 1996) . As both raltitrexed and CPT-11 have demonstrated activity against CRC, and are known to act by different molecular mechanisms, there is a possibility that synergism may be observed if both drugs are given together in patients with this disease.
Preclinical in vitro studies carried out in cloned human cell lines with raltitrexed and SN 38, the active metabolite of CPT-11, have shown evidence of synergism between the two agents (Aschele et al, 1995, 1996a and . In particular, Aschele et al (1996a) showed that sequential rather than simultaneous administration resulted in Raltitrexed with 5-FU As described previously, raltitrexed and 5-FU have both been shown in clinical studies to be effective as single agents in the treatment of advanced CRC. Both drugs share TS as a common target, but raltitrexed inhibits this enzyme directly and specifically. Some metabolites of 5-FU are incorporated into RNA, so 5-FU inhibits both DNA and RNA synthesis. The degree of RNA inhibition appears to be schedule dependent (Sobrero et al, 1997) . A combination of the two drugs may therefore produce a more complete blockade of TS than either agent alone. Furthermore, increased activity against heterogeneous cell populations might be conferred by the exclusivity of modes of drug uptake and metabolism. As Figure 6 The action of topoisomerase on DNA transcription both drugs are active in advanced CRC, combination of the two would be expected to enhance their respective cytotoxic effects.
Evidence from preclinical studies supports the use of combination therapy with raltitrexed and 5-FU. Raltitrexed is already known to increase the incorporation of fluorouracil phosphate into RNA if administered before 5-FU (Izzo et al, 1995) . Preclinical studies with human CRC cell lines HT-29 and HCT-8 have shown synergistic interactions between raltitrexed and 5-FU (Chang et al, 1994; Izzo et al, 1995; Kimbell et al, 1996) . When 5-FU was given for 1 h before 24-h incubation with raltitrexed, strong antagonism of the cytotoxic effect was seen with high doses of 5-FU and low doses of raltitrexed. However, low doses of 5-FU and high doses of raltitrexed resulted in synergism. Harstrick (1995) has reported that an overall pattern of additivity is shown by isobole analysis of this sequence (Figure 7) . Notably, reversal of the schedules, so that raltitrexed was used first, caused synergism for all drug ratios (Izzo, 1995) .
The main toxic effects of 5-FU are mucositis and diarrhoea, myelosuppression and skin disorders. As well as diarrhoea, raltitrexed is associated with leucopenia, and so myelosuppression is common to both agents. However, the severity of this effect may be reduced if 5-FU is given as a prolonged infusion; one of the clinical trials described in this section takes advantage of this. Furthermore, mucositis and leucopenia appear to be markedly less frequent and less severe with raltitrexed than with 5-FU (Zalcberg, 1997) .
A review of preclinical and clinical literature on the anti-tumour and toxic effects of 5-FU has indicated that this drug appears to act in different ways when given according to different dose schedules, most notably bolus or continuous infusion (Sobrero, 1997) . To investigate this premise, two phase I clinical studies of raltitrexed in combination with 5-FU in patients with advanced CRC are under way. The first, which is being conducted in the USA, involves patients with advanced metastatic or recurrent, unresectable colorectal cancer (Schwartz et al, 1997) . Objectives are to determine the MTD, toxicity and anti-tumour activity of raltitrexed followed after 24 h by 5-FU given as a rapid intravenous infusion. Follow-up is 28 days after the final dose and tolerability is to be assessed in terms of haematology, biochemistry and adverse event reports. Dosage levels have been raltitrexed 0.5, 1.0, 1.5, 2.0, 2.5 or 3.0 mg m-2 with 5-FU 900 mg m-2 every 3 weeks; these have recently been increased to raltitrexed 3.0 mg m-2 with 5-FU 1200 mg m-2, with the intention to further increase the 5-FU dose to 1500 mg m-2. Preliminary data in 12 patients who have received raltitrexed at a dose of up to 2.0 mg m-2 showed two partial responses in pretreated patients. In addition, six patients had stable disease lasting from 3.7 to at least Table 5 Synergism (indicated by combination indices) between raltitrexed (R) and SN 38, the active metabolite of CPT-11, in HCT-8 human colon cancer cells (Aschele et al, 1995; 1996a) Inhibition of cell proliferation (%)
Sequential 4 (Moertel, 1994 Radiotherapy is often prescribed in an attempt to reduce the risk of tumour recurrence. Administration of post-operative 5-FU in combination with radiotherapy resulted in a 15% survival advantage and lower incidences of metastases and local recurrence in one study (Mayer et al, 1989) cell killing by radiation. However, raltitrexed was a more effective ollowed by raltitrexed (24 h); pattern suggests additivity addition than 5-FU (Teicher and Coleman, 1997) . Cells were tested under euoxic and hypoxic conditions. As shown in Table 8 , raltitrexed 0.5 or 1 ,UM increased radiation-induced cell killing to a (Schwartz et al, 1997) . Most recent data from 17 markedly greater extent than 5-FU 10 uMunder euoxic conditions. -ate that 70% have stable disease (some for up to 12
In the transplantable Lewis lung carcinoma cell line, raltitrexed how a complete response in a non-pretreated patient. showed a radiation dose-modifying effect of 1.5. Raltitrexed is een some dose delays due to neutropenia but none of believed to achieve this effect through the inhibition of repair of patients have withdrawn from treatment. No DLT or radiation-induced DNA strand breaks in euoxic and hypoxic cells 6icity has been reported to date.
and by interaction with radiation in hypoxic cells. d phase I study is being conducted at a single German Two phase I studies in the UK are currently investigating tients with untreated advanced or metastatic CRC.
combinations of raltitrexed 2.0, 2.6 and 3.0 mg m-2 with radioe to determine the MTD and to assess the pharmacotherapy (given as 28 fractions of 1.8 Gy 5 times weekly for 5-6 harmacodynamic profile of raltitrexed on days 8 and weeks) in patients with resected or inoperable/recurrent rectal British Joumal of Cancer (1998) (Figure 8 ). The investigators aim to recruit 18 patients to each study to determine the optimum dosage of raltitrexed to be used as combination treatment with radiotherapy. As in other studies discussed, safety is being assessed in terms of adverse event reports and haematological and biochemical parameters. MTD has not yet been reached at level 2, and the major toxicities to date are asthenia and diarrhoea. Interestingly, raltitrexed does not appear to sensitize normal tissue to radiation.
CONCLUSIONS
Following the extensive monotherapy clinical trial programme in advanced CRC, raltitrexed is now being investigated in combination with other cytotoxic agents and as adjuvant treatment for earlier stages of the disease. The direct and specific mode of action of raltitrexed offers exciting new opportunities for more effective cytotoxic treatments in a range of malignancies. Initial encouraging results in other tumour types have led to the initiation of monotherapy and combination studies in head and neck, prostate, lung, breast, gastric, colorectal, ovarian and adrenal cancers, and in paediatric malignancies and advanced soft tissue sarcoma. The significant single-agent anti-tumour activity (comparable to modulated 5-FU regimens in advanced CRC) and early evidence of synergistic activity in combination with 5-FU and/or CPT-1 1 offer for the first time the possibility of a stepped increase in the effectiveness of chemotherapy in this disease. The lack of toxicity seen with raltitrexed in combination with CPT-11 is both scientifically interesting and clinically exciting, and indicates that improvements in efficacy may be achieved with no deterioration in tolerability. Available data from the combination studies show that all treatments have been well tolerated so far. As further data emerge, it will be possible to evaluate more fully the broad contribution of raltitrexed to the treatment of cancer.
